Chemistry:Bivatuzumab
From HandWiki
Short description: Chemical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD44 v6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| (verify) | |
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]
It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer".[3] Prior to 2002 it was described as targeting CD44 v8.[4]
It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer.[1]
It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.
References
- ↑ 1.0 1.1 "Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer". Journal of Nuclear Medicine 44 (10): 1690–9. October 2003. PMID 14530488. http://jnm.snmjournals.org/cgi/content/abstract/44/10/1690.
- ↑ "Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma". Clinical Cancer Research 9 (10 Pt 2): 3961S–72S. September 2003. PMID 14506195. https://clincancerres.aacrjournals.org/content/9/10/3961s.short.
- ↑ "Amendments to Previous Lists". WHO Drug Information 16 (3). 2002. http://digicollection.org/hss/en/d/Js4951e/8.html.
- ↑ "Recommended INN: List 45". WHO Drug Information 15 (1): 4. 2001. https://apps.who.int/iris/bitstream/handle/10665/75047/INN_2001_list45.pdf?sequence=1&isAllowed=y.
 |  |
